Source comparison
How to Run MK-677 Cycle: Protocol Comparison
8 weeks 25mg/day evening Baseline + Week 8 Exploratory short-term studies where extended protocols aren't feasible Fasting glucose at baseline and week 4 Too short to capture full anabolic window. IGF-1 peaks around week 4–6, leaving minimal exposure at therap
This comparison does not assign a generated winner or score.
- 8 weeks
- 25mg/day evening
- Baseline + Week 8
- Exploratory short-term studies where extended protocols aren't feasible
- Fasting glucose at baseline and week 4
- Too short to capture full anabolic window. IGF-1 peaks around week 4–6, leaving minimal exposure at therapeutic elevation
- 12 weeks
- Baseline + Week 6 + Week 12
- Standard protocol for body composition research with adequate monitoring
- Fasting glucose biweekly
- Minimum viable duration. Captures IGF-1 peak and allows 6–8 weeks of sustained elevation for downstream signalling
- 16 weeks
- Baseline + Week 4 + Week 10 + Week 16
- Extended protocol for collagen synthesis, joint health, or metabolic studies
- Fasting glucose biweekly + HbA1c at week 8
- Ideal balance. Maximises time in elevated IGF-1 state without excessive glucose exposure risk
- 24 weeks
- Baseline + Monthly through Week 24
- Long-term growth hormone research requiring sustained elevation
- Fasting glucose weekly + HbA1c quarterly
- Maximum research-appropriate duration before diminishing returns. Beyond 24 weeks adds cost without proportional benefit
- >24 weeks
- Baseline + Monthly indefinitely
- Chronic deficiency states (not recreational research)
- Fasting glucose weekly + HbA1c quarterly + OGTT biannually
- Not recommended for standard protocols. Cumulative insulin resistance risk outweighs incremental IGF-1 benefits